This webinar discusses how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients. Paolo A. Ascierto, MD of Italy’s National Tumor Institute and Kamil Sklodowski of Biognosys elaborate on the promise of proteomics for addressing the unmet medical needs of melanoma patients undergoing immunotherapy.
GenomeWebinar June 16, 2021
Precision Oncology in Melanoma Patients Treated with Immunotherapy: Clinical and Technological Perspective
Access our knowledge base with relevant resources and guiding information.